Supira's technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients with a single device
/PRNewswire/ Supira Medical, Inc., a Shifamed portfolio company, announced today that the company s percutaneous ventricular assist device (pVAD) will be.
Balazs Halmos, MD, discusses factors to consider when selecting a biomarker assay for patients with non–small cell lung cancer, emphasizes the importance of secondary testing, provides recommendations for the treatment of patients with co-mutations, and highlights ongoing or future areas of interest for research within lung cancer.
/PRNewswire/ Supira Medical, Inc., a Shifamed portfolio company, announced today that leading U.S. interventional cardiologist, Dr. Azeem Latib, has joined.